| 摘要 |
<p>The present invention generally relates to a novel process for preparing vitronectin receptor antagonist compounds having a benzodiazepinyl core structure. This invention relates to the preparation of pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis. In particular, the present invention relates to a novel process for preparing (±)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}- 2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid, (R)-3-oxo-8- {[3-(pyridin-2-ylamino) propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-lH-2- benzazepine-4-acetic acid and (S)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2- trifluoroethyl)-2,3,4,5-tetrahydro-lH-2-benzazepine-4-acetic acid or a pharmaceutically acceptable salt thereof.</p> |
